Journal Guide
JAMA Oncology Impact Factor 20.1: Publishing Guide
Clinical oncology with methodological excellence: where rigorous science meets cancer care
20.1
Impact Factor (2024)
~8%
Acceptance Rate
~21 days
Time to First Decision
What JAMA Oncology Publishes
JAMA Oncology combines the American Medical Association's commitment to clinical excellence with specialized oncology expertise. They want methodologically rigorous studies that advance cancer care through high-quality clinical research, outcomes analysis, and epidemiology.
- Clinical trials with rigorous methodology and clear practice implications
- Outcomes research that informs cancer care quality and delivery
- Cancer epidemiology studies with population-level insights
- Health services research addressing cancer care access and quality
- Methodological innovations in cancer research design and analysis
Editor Insight
“JAMA Oncology serves practicing oncologists who need methodologically sound evidence to guide patient care. We want research that's so well-designed and clearly presented that it becomes the standard reference for clinical decision-making.”
What JAMA Oncology Editors Look For
Exceptional methodological rigor
JAMA Oncology has among the most stringent methodological standards in oncology. Every aspect of study design, analysis, and reporting must be bulletproof.
Clinical trial excellence
Phase 3 trials with clear primary endpoints, appropriate statistics, and practice-changing results. Protocol adherence and reporting standards are scrutinized intensely.
Outcomes research that matters
Studies that show how we can deliver better cancer care. Quality measures, survival outcomes, and real-world effectiveness are key themes.
Population-level perspective
Research that addresses cancer care across populations, not just individual patients. Disparities, access, and health equity considerations are valued.
Immediate clinical applicability
Like all JAMA journals, the focus is on research that practicing oncologists can use. Academic exercises without clinical relevance face skepticism.
Transparent and complete reporting
Full disclosure of methods, limitations, conflicts, and funding. Any hint of selective reporting or hidden data is fatal.
Why Papers Get Rejected
These patterns appear repeatedly in manuscripts that don't make it past JAMA Oncology's editorial review:
Methodological shortcuts or omissions
JAMA Oncology's statistical review is thorough. Underpowered studies, inappropriate analyses, or missing data handling will be caught and criticized.
Single-institution studies without broader validation
Results from one cancer center raise generalizability questions. Multi-site studies or validation in external cohorts strengthen claims significantly.
Incomplete trial reporting
CONSORT guidelines aren't suggestions. Missing flow diagrams, unreported outcomes, or protocol deviations without explanation damage credibility.
Overinterpreting secondary endpoints
If your primary endpoint didn't meet significance, spinning secondary analyses as practice-changing doesn't work. Be honest about what you've proven.
Ignoring health equity implications
If your research has implications for cancer disparities or access to care, address this explicitly. JAMA Oncology increasingly values equity perspectives.
Weak clinical implications section
How does this change practice? What should oncologists do differently? If you can't articulate clear clinical implications, rethink your submission.
Does your manuscript avoid these patterns?
The quick diagnostic reads your full manuscript against JAMA Oncology's criteria and flags the specific issues most likely to cause rejection.
Insider Tips from JAMA Oncology Authors
Statistical review is exceptionally thorough
JAMA Oncology employs dedicated biostatisticians who will scrutinize every analysis. Get statistical review before submission, not after.
Negative trials are welcomed if well-designed
Definitive negative results that prevent adoption of ineffective treatments are valued. Don't spin negative results; embrace them if methodologically sound.
Real-world evidence studies are increasingly important
Registry studies, administrative database analyses, and population-based cohorts that complement trial data are in demand.
Health equity research gets editorial attention
Studies addressing cancer disparities, rural access, or socioeconomic barriers to care align with JAMA's social justice mission.
Clinical guidelines influence often cited
Studies that directly inform NCCN, ASCO, or other guidelines get extra attention. Frame your work in terms of guideline implications.
Patient-reported outcomes are increasingly required
Quality of life, functional status, and patient experience measures strengthen clinical trial submissions significantly.
Meta-analyses need exceptional rigor
If submitting systematic reviews, adherence to PRISMA guidelines and thorough search strategies are essential.
AMA connections don't hurt but aren't required
Work affiliated with AMA initiatives may get extra consideration, but methodological excellence trumps politics.
The JAMA Oncology Submission Process
Presubmission inquiry (rarely used)
Response within 1 week if submittedJAMA Oncology prefers full submissions. Inquiries mainly for highly unusual study types.
Full submission
Initial decision ~21 daysComplete manuscript with emphasis on methodological rigor and clinical relevance. Structured abstract required.
Editorial and statistical review
~2-3 weeksConcurrent editorial and methodological assessment. High desk rejection rate for methodologically weak studies.
Peer review
3-4 weeksClinical oncologists and methodological experts. Focus on rigor, clinical significance, and practice implications.
Revision
Authors expected to respond efficientlyRevision requests typically focused on specific methodological concerns or clinical interpretation issues.
JAMA Oncology by the Numbers
| 2024 Impact Factor(Clarivate JCR) | 28.4 |
| Submissions per year | ~2,800 |
| Acceptance rate | ~8% |
| Desk rejection rate | ~70% |
| Time to first decision | 21 days median |
| Post-review acceptance | ~25% of reviewed |
| Monthly publication | 12 issues/year |
| AMA oncology membership | Part of larger AMA community |
Before you submit
JAMA Oncology accepts a small fraction of submissions. Make your attempt count.
The pre-submission diagnostic runs a live literature search, scores your manuscript section by section, and gives you a prioritized fix list calibrated to JAMA Oncology. ~30 minutes.
Article Types
Original Investigation
3,500 wordsFull clinical research reports with practice implications
Brief Report
1,500 wordsConcise reports of important clinical findings
Review
4,000 wordsSystematic reviews and meta-analyses
Viewpoint
1,200 wordsOpinion pieces on cancer care and policy
Landmark JAMA Oncology Papers
Papers that defined fields and changed science:
- Radical vs. conservative surgery in breast cancer - long-term outcomes (Fisher et al., 2017)
- Immune checkpoint inhibitor toxicity - population-based analysis (Puzanov et al., 2017)
- Cancer screening in older adults - guideline recommendations (Wolf et al., 2018)
- Financial toxicity of cancer care - national survey (Zafar et al., 2019)
- Telemedicine in oncology during COVID-19 - practice patterns (Lonergan et al., 2020)
Preparing a JAMA Oncology Submission?
Get pre-submission feedback from reviewers who've published in JAMA Oncology and know exactly what editors look for.
Run Free Readiness ScanNeed expert depth? Human review from $1,000
Primary Fields
Ready to submit to JAMA Oncology?
A desk rejection costs months. Get expert feedback before you submit, from scientists who know exactly what JAMA Oncology editors look for.
Avoid Desk Rejection
Get expert pre-submission review before you submit to JAMA Oncology. 3-7 day turnaround.
Manuscript Rejected?
Expert revision help to strengthen your manuscript and resubmit with confidence.
Reviewer Response Help
Get expert guidance crafting your response to JAMA Oncology reviewers.
Need field-expert depth? Human review from $1,000